Can AVNS sustain its Q4 2024 earnings growth?

**Avanos Medical Inc (AVNS) faces challenges in sustaining its Q4 2024 earnings growth** due to several factors:

1. **Decline in HA Portfolio**: The HA portfolio experienced a significant decline of more than 30% year-over-year, which had a substantial impact on overall revenue growth. This decline is a major headwind for AVNS's earnings sustainability.
2. **Softness in Pain Management Portfolio**: There was softness in the North America COOLIEF offering, affecting the overall pain portfolio performance. This indicates that the pain management segment is not performing optimally, which could negatively affect earnings growth.
3. **Supply Chain Challenges**: The company faced supply challenges, particularly in the ON-Q product line, which underperformed due to these issues and higher-than-expected customer turnover. These supply chain challenges can impact revenue and growth expectations.
4. **Market Conditions and Competition**: The medical equipment industry is competitive, and AVNS faces market conditions that could impact its ability to sustain growth. The company must navigate pricing pressures and volume share gains in the HA portfolio.

In conclusion, while AVNS has shown strong performance in some areas, such as its Digestive Health portfolio and Game Ready portfolio, the significant declines in the HA and pain management portfolios, along with supply chain challenges, create uncertainty around the sustainability of its Q4 2024 earnings growth. The company will need to address these issues and maintain its performance in key growth areas to sustain earnings momentum.